全文获取类型
收费全文 | 70500篇 |
免费 | 4238篇 |
国内免费 | 1516篇 |
专业分类
耳鼻咽喉 | 103篇 |
儿科学 | 1841篇 |
妇产科学 | 805篇 |
基础医学 | 5089篇 |
口腔科学 | 529篇 |
临床医学 | 9325篇 |
内科学 | 23053篇 |
皮肤病学 | 188篇 |
神经病学 | 1252篇 |
特种医学 | 1650篇 |
外国民族医学 | 1篇 |
外科学 | 9073篇 |
综合类 | 10614篇 |
现状与发展 | 3篇 |
预防医学 | 2866篇 |
眼科学 | 94篇 |
药学 | 6018篇 |
47篇 | |
中国医学 | 3063篇 |
肿瘤学 | 640篇 |
出版年
2023年 | 987篇 |
2022年 | 1632篇 |
2021年 | 2660篇 |
2020年 | 2451篇 |
2019年 | 2414篇 |
2018年 | 2414篇 |
2017年 | 2027篇 |
2016年 | 2118篇 |
2015年 | 2299篇 |
2014年 | 4762篇 |
2013年 | 5010篇 |
2012年 | 3781篇 |
2011年 | 4508篇 |
2010年 | 3645篇 |
2009年 | 3670篇 |
2008年 | 3564篇 |
2007年 | 3528篇 |
2006年 | 3244篇 |
2005年 | 2939篇 |
2004年 | 2298篇 |
2003年 | 2023篇 |
2002年 | 1640篇 |
2001年 | 1566篇 |
2000年 | 1213篇 |
1999年 | 1014篇 |
1998年 | 840篇 |
1997年 | 800篇 |
1996年 | 721篇 |
1995年 | 662篇 |
1994年 | 614篇 |
1993年 | 468篇 |
1992年 | 458篇 |
1991年 | 412篇 |
1990年 | 347篇 |
1989年 | 352篇 |
1988年 | 343篇 |
1987年 | 261篇 |
1986年 | 218篇 |
1985年 | 255篇 |
1984年 | 243篇 |
1983年 | 168篇 |
1982年 | 190篇 |
1981年 | 185篇 |
1980年 | 189篇 |
1979年 | 158篇 |
1978年 | 140篇 |
1977年 | 124篇 |
1976年 | 119篇 |
1975年 | 110篇 |
1973年 | 97篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
141.
重组人红细胞生成素治疗肾性贫血的临床分析 总被引:1,自引:0,他引:1
目的 观察重组人红细胞生成素 (RhEPO)对肾性贫血的治疗作用。方法 根据使用EPO剂量的不同将 39例慢性肾衰竭并血液透析病人分成 4组 ,观察治疗后 2、4、12个月时与治疗前 (0月 )相比红细胞数 (RBC)、红细胞比积 (Hct)及血红蛋白含量 (Hb)的变化。结果 2 4例使用EPO10 0 - 15 0IU/ (kg·w) (6 0 0 0IU/w - 90 0 0IU/w) ,治疗后RBC、Hct、Hb较治疗前有显著升高 (P≤ 0 .0 0 1) ;5例使用EPO5 0IU/ (kg·w) (30 0 0IU/w) +间断输血患者 ,其RBC、Hct、Hb升高不显著 ;10例不用EPO而单纯输血患者 ,其RBC、Hct、Hb无明显变化 (P >0 .0 5 )。结论 EPO能较好地纠正肾性贫血 ;单纯输血不能治疗肾性贫血 相似文献
142.
R S Rodger W L Sheldon M J Watson J H Dewar R Wilkinson M K Ward D N Kerr 《Nephrology, dialysis, transplantation》1989,4(10):888-892
We selected a group of male dialysis patients complaining of sexual dysfunction in whom penile vascular insufficiency and drug-induced impotence had been excluded. Monitoring of nocturnal penile tumescence was used to confirm organic disturbance. Patients with normal serum prolactin concentrations (n = 18) had significantly lower serum zinc values than normal controls (P less than 0.001) and were entered in a 6-month double-blind study comparing oral zinc acetate with placebo. Patients with elevated prolactin concentrations (n = 8) were entered in a 3-month double-blind crossover study comparing oral pergolide mesylate with placebo. In the zinc study, serum zinc concentrations increased (P less than 0.05) in the zinc-treated but not the placebo-treated group. One of nine patients receiving zinc reported improved sexual function, as did two of nine patients receiving placebo. There were no significant changes in sperm counts, nocturnal penile tumescence, testosterone, sex hormone binding globulin or gonadotrophin concentrations in either treatment group. In the pergolide study, serum prolactin values decreased (P less than 0.01) in the pergolide but not in the placebo treatment period. One patient reported improved sexual function during the pergolide treatment period and two during the placebo period. There were no significant changes in sperm counts, nocturnal penile tumescence, testosterone, sex hormone binding globulin or gonadotrophin concentrations after pergolide. These studies show no benefit of zinc or pergolide compared with placebo in the treatment of uraemic impotence. 相似文献
143.
144.
山莨菪碱对梗阻性黄疸心脏的保护作用 总被引:1,自引:0,他引:1
目的 观察梗阻性黄疸时山莨菪碱对心脏的保护作用。方法将30只成年Wistar大鼠随机分为假手术组和梗阻性黄疸模型组;模型组包括山莨菪碱治疗组,生理盐水对照组。分别于术后第14、28天测定各组血浆内毒素含量,观察心肌病理、酶组织化学和心率改变及山莨菪碱治疗后的变化。结果生理盐水对照组血浆内毒素水平明显升高,心肌出现变性、局灶坏死、线粒体破损等病理改变,心肌组织琥珀酸脱氢酶、腺苷三磷酸酶活性明显降低(P<0.05),而酸性磷酸酶活性明显增强(P<0.05),心率明显减缓(P<0.05),山莨菪碱治疗组则以上情况均有明显改善(P>0.05)。结论 山莨菪碱对梗阻性黄疸时心脏有保护作用。 相似文献
145.
目的评价β-受体阻滞剂治疗老年冠心病慢性心力衰竭的疗效及安全性。方法105例老年冠心病慢性心力衰竭患者按就诊顺序随机分为两组,美托洛尔组52例在常规抗心力衰竭治疗基础上加用美托洛尔12.5~25mg,2/d;对照组53例采用常规抗心力衰竭治疗,未用美托洛尔。定期来诊随访,观察临床表现,监测治疗前后心率、血压、心功能参数变化。结果美托洛尔组显效率53.8%,总有效率88.5%;对照组显效率30.2%,总有效率67.9%,两者比较有显著性差异(P〈0.05)。美托洛尔组患者心率减慢、血压降低较对照组明显,超声心动图复查显示治疗6个月后左室舒张末期内径缩小,左室射血分数增高较对照组显著。结论美托洛尔为老年冠心病慢性心力衰竭提供一种较为安全有效的药物治疗手段。 相似文献
146.
目的:研究血小板的活化状态在先天性心脏病中的作用。方法:采用流式细胞术测定P选择素的表达作为血小板活化的特异性指标,患者分为非紫绀组32例、紫绀组9例、健康对照组12例.研究先天性心脏病患者血小板活化功能的变化。结果:与健康对照组相比,非紫绀组和紫绀组先天性心脏病患者P选择素的表达均明显升高,紫绀组尤为显著。结论:先天性心脏病患者存在血小板的活化状态,紫绀型先天性心脏病更明显,这可能是引起这些患者止血功能异常的原因之一。 相似文献
147.
Yukiko Hasuike Takeshi Nakanishi Rintarou Moriguchi Yoshinaga Otaki Masayoshi Nanami Yasue Hama Miki Naka Koji Miyagawa Masaaki Izumi Yoshihiro Takamitsu 《Nephrology, dialysis, transplantation》2004,19(6):1474-1479
BACKGROUND: Cyanide is a toxic agent, and its detoxification product, thiocyanate, may be a major pathogenetic substance in uraemia. Recent studies examining the myeloperoxidase(MPO)/thiocyanate system have suggested a link between thiocyanate and atherosclerosis. However, inaccuracies in conventional assays for cyanide and thiocyanate have limited the understanding of their metabolism in haemodialysis (HD) patients. METHODS: We used high-performance liquid chromatography to measure cyanide in erythrocytes and thiocyanate in plasma in 43 HD patients and in a group of 46 healthy controls that included 15 current smokers. To clarify the metabolic conversion of cyanide to thiocyanate in uraemic patients, we also measured cysteine and sulfate. We then used stepwise regression analysis to analyse factors that determine erythrocyte cyanide and plasma thiocyanate. RESULTS: Mean cyanide and thiocyanate were significantly greater in HD patients than in non-smoking controls. However, cyanide was far below lethal concentrations in dialysis patients. Thiocyanate was six to seven times greater in HD patients than in non-smoking controls, and decreases in thiocyanate following dialysis were only 19.3+/-3.5%. Multiple regression analysis showed a positive correlation between cyanide and thiocyanate in controls, but a negative correlation in HD patients. In patients, an inverse relationship between thiocyanate and BUN was also observed. CONCLUSIONS: The elevation of thiocyanate in patients undergoing dialysis probably is secondary to both limited efficiency of HD and deranged metabolism of cyanide and thiocyanate. Because thiocyanate is a preferred substrate for MPO, it may play a role in uraemic complications including cardiovascular events. 相似文献
148.
目的总结瓣膜置换患者行胆道手术的术前用药方法。方法对38例瓣膜置换后在服用华法令过程中因胆道疾病需行择期手术治疗的患者随机分为2组,肝功能正常组(A组)23例、肝功能不正常组(B组)15例均于术前3d停服华法令,B组术前12h肌注VitK110mg。术前无应用华法令历史的患者115例做为对照组。结果38例患者停药2d后A组血浆凝血酶原时间与对照组差异无显著意义,B组于术前12h肌注VitK110mg后,血浆凝血酶原时间与对照组相比差异也无显著性意义。结论瓣膜置换患者在抗凝期间行胆道手术,只要准备充分,围手术期是安全的。 相似文献
149.
Darren S Parsons David A Reaveley Darrell V Pavitt Madhukar Misra Edwina A Brown 《Nephrology, dialysis, transplantation》2003,18(9):1848-1853
BACKGROUND: Studies have reported an increase in median Lipoprotein (Lp) (a) in patients with high molecular weight (HMW) apolipoprotein (apo) (a) isoforms and renal impairment. Some studies identify Lp (a) levels as a risk factor for vascular disease in renal failure whilst others have demonstrated an association with apo (a) isoform type and vascular disease. METHODS: A total of 239 patients at end-stage renal failure (ESRF) were studied prior to the initiation of dialysis. Blood was taken for Lp (a) levels and apo (a) isoforms. Clinical vascular disease (CVD) was assessed on the basis of clinical history and Rose questionnaire. The control group for Lp (a) levels consisted of 228 healthy volunteers. RESULTS: Despite a higher median Lp (a) level in those with HMW isoforms, 30% of patients had Lp (a) levels <10 mg/dl. Overall, 49% patients were identified as having CVD. Diabetes, smoking history and Lp (a) levels were significantly associated with CVD in logistic regression analysis, although when patients with low molecular weight (LMW) and HMW isoforms were analysed separately, Lp (a) levels were not significantly associated with CVD in those with LMW isoforms. The rates of CVD in those with HMW isoform and low Lp (a) levels were significantly lower than those with HMW isoforms and elevated Lp (a) levels, 34 vs 57% (P < 0.01). CONCLUSIONS: Although median Lp (a) levels in those patients at ESRF with HMW isoforms are higher than controls, in a third of such patients Lp (a) levels remain relatively low. These patients have lower rates of CVD than those with high levels of Lp (a). 相似文献
150.
慢性阻塞性肺疾病前驱性呼吸衰竭患者呼吸驱动的改变 总被引:15,自引:4,他引:11
目的探讨慢性阻塞性肺疾病(COPD)和COPD前驱性呼吸衰竭(前驱呼衰)患者中枢呼吸驱动的改变;评价界定COPD前驱性呼吸衰竭的临床意义.方法试验对象为COPD前驱性呼吸衰竭、COPD尚未达前驱性呼吸衰竭的患者和健康对照者各30名.所有受试者均进行如下参数的测定:动脉血气分析;常规肺功能,主要以第1秒用力呼气容积(FEV1)占预计值的百分比(FEV1%)来评价;中枢呼吸驱动水平,以0.1 s口腔阻断压(P0.1)、校正中枢呼吸驱动(以每分通气量来校正,即P0.1/MV)和吸气阻抗P0.1/VT/Ti)等来评价.结果P0.1和P0.1/MV在COPD前驱呼衰组明显高于正常对照组和未达前驱呼衰组,P0.1/VT/Ti在COPD前驱呼衰组和未达前驱呼衰组明显高于正常对照组(P=0.002);P0.1,P0.1/MV,P0.1/VT/Ti与PaO2,FEV1%呈显著负相关(rs=-0.769,-0.495,-0.543;-0.747,-0.480,-0.526,P均<0.01);与PaCO2呈显著正相关(rs=0.270,0.312,0.369,P分别为<0.05,<0.01,<0.01).结论COPD前驱呼衰患者呼吸储备能力减低,呼吸效率下降;P0.1,P0.1/MV,P0.1/VT/Ti等参数在推断患者神经-肌力输出水平与呼吸衰竭发生阈值方面具有较大的意义.当COPD进展至前驱呼衰阶段,从血气分析、肺功能检查到呼吸驱动水平都发生了显著的改变,从而提示界定此阶段具有一定的临床意义. 相似文献